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EXECUTIVE SUMMARY
1. Foot infections in patients with diabetes cause
substantial morbidity and frequent visits to health care
professionals and may lead to amputation of a lower
extremity.
2. Diabetic foot infections require attention to local
(foot) and systemic (metabolic) issues and coordinated
management, preferably by a multidisciplinary foot-
care team (A-II) (table 1). The team managing these
infections should include, or have ready access to, an
infectious diseases specialist or a medical microbiologist
(B-II).
3. The major predisposing factor to these infections
is foot ulceration, which is usually related to peripheral
neuropathy. Peripheral vascular disease and various im-
munological disturbances play a secondary role.
4. Aerobic gram-positive cocci (especially Staphy-
lococcus aureus) are the predominant pathogens in
diabetic foot infections. Patients who have chronic
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wounds or who have recently received antibiotic ther-
apy may also be infected with gram-negative rods, and
those with foot ischemia or gangrene may have obligate
anaerobic pathogens.
5. Wound infections must be diagnosed clinically
on the basis of local (and occasionally systemic) signs
and symptoms of inflammation. Laboratory (including
microbiological) investigations are of limited use for
diagnosing infection, except in cases of osteomyelitis
(B-II).
6. Send appropriately obtained specimens for cul-
ture prior to starting empirical antibiotic therapy in all
cases of infection, except perhaps those that are mild
and previously untreated (B-III). Tissue specimens ob-
tained by biopsy, ulcer curettage, or aspiration are pref-
erable to wound swab specimens (A-I).
7. Imaging studies may help diagnose or better de-
fine deep, soft-tissue purulent collections and are usu-
ally needed to detect pathological findings in bone.
Plain radiography may be adequate in many cases, but
MRI (in preference to isotope scanning) is more sen-
sitive and specific, especially for detection of soft-tissue
lesions (A-I).
8. Infections should be categorized by their severity
on the basis of readily assessable clinical and laboratory
features (B-II). Most important among these are the
specific tissues involved, the adequacy of arterial per-
fusion, and the presence of systemic toxicity or meta-
bolic instability. Categorization helps determine the de-
gree of risk to the patient and the limb and, thus, the
urgency and venue of management.
9. Available evidence does not support treat-
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Table 1. Infectious Diseases Society of America–United States Public Health Service Grading System for ranking rec-
ommendations in clinical guidelines.
Category, grade Definition
Strength of recommendation
A Good evidence to support a recommendation for use; should always be offered
B Moderate evidence to support a recommendation for use; should generally be offered
C Poor evidence to support a recommendation; optional
D Moderate evidence to support a recommendation against use; should generally not be offered
E Good evidence to support a recommendation against use; should never be offered
Quality of evidence
I Evidence from 1 properly randomized, controlled trial
II Evidence from 1 well-designed clinical trial, without randomization; from cohort or case-
controlled analytic studies (preferably from 11 center); from multiple time-series; or from
dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical experience, descriptive
studies, or reports of expert committees
ing clinically uninfected ulcers with antibiotic therapy (D-III).
Antibiotic therapy is necessary for virtually all infected wounds,
but it is often insufficient without appropriate wound care.
10. Select an empirical antibiotic regimen on the basis of
the severity of the infection and the likely etiologic agent(s)
(B-II). Therapy aimed solely at aerobic gram-positive cocci may
be sufficient for mild-to-moderate infections in patients who
have not recently received antibiotic therapy (A-II). Broad-
spectrum empirical therapy is not routinely required but is
indicated for severe infections, pending culture results and an-
tibiotic susceptibility data (B-III). Take into consideration any
recent antibiotic therapy and local antibiotic susceptibility data,
especially the prevalence of methicillin-resistant S. aureus
(MRSA) or other resistant organisms. Definitive therapy should
be based on both the culture results and susceptibility data and
the clinical response to the empirical regimen (C-III).
11. There is only limited evidence with which to make
informed choices among the various topical, oral, and paren-
teral antibiotic agents. Virtually all severe and some moderate
infections require parenteral therapy, at least initially (C-III).
Highly bioavailable oral antibiotics can be used in most mild
and in many moderate infections, including some cases of os-
teomyelitis (A-II). Topical therapy may be used for some mild
superficial infections (B-I).
12. Continue antibiotic therapy until there is evidence that
the infection has resolved but not necessarily until a wound
has healed. Suggestions for the duration of antibiotic therapy
are as follows: for mild infections, 1–2 weeks usually suffices,
but some require an additional 1–2 weeks; for moderate and
severe infections, usually 2–4 weeks is sufficient, depending on
the structures involved, the adequacy of debridement, the type
of soft-tissue wound cover, and wound vascularity (A-II); and
for osteomyelitis, generally at least 4–6 weeks is required, but
a shorter duration is sufficient if the entire infected bone is
removed, and probably a longer duration is needed if infected
bone remains (B-II).
13. If an infection in a clinically stable patient fails to re-
spond to 1 antibiotic courses, consider discontinuing all an-
timicrobials and, after a few days, obtaining optimal culture
specimens (C-III).
14. Seek surgical consultation and, when needed, interven-
tion for infections accompanied by a deep abscess, extensive
bone or joint involvement, crepitus, substantial necrosis or gan-
grene, or necrotizing fasciitis (A-II). Evaluating the limb’s ar-
terial supply and revascularizing when indicated are particularly
important. Surgeons with experience and interest in the field
should be recruited by the foot-care team, if possible.
15. Providing optimal wound care, in addition to appro-
priate antibiotic treatment of the infection, is crucial for healing
(A-I). This includes proper wound cleansing, debridement of
any callus and necrotic tissue, and, especially, off-loading of
pressure. There is insufficient evidence to recommend use of
a specific wound dressing or any type of wound healing agents
or products for infected foot wounds.
16. Patients with infected wounds require early and careful
follow-up observation to ensure that the selected medical and
surgical treatment regimens have been appropriate and effective
(B-III).
17. Studies have not adequately defined the role of most
adjunctive therapies for diabetic foot infections, but systematic
reviews suggest that granulocyte colony-stimulating factors and
systemic hyperbaric oxygen therapy may help prevent ampu-
tations (B-I). These treatments may be useful for severe infec-
tions or for those that have not adequately responded to ther-
apy, despite correcting for all amenable local and systemic
adverse factors.
18. Spread of infection to bone (osteitis or osteomyelitis)
may be difficult to distinguish from noninfectious osteoar-
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Table 2. Risk factors for foot ulceration and infection.
Risk factor Mechanism of injury or impairment
Peripheral motor neuropathy Abnormal foot anatomy and biomechanics, with clawing of
toes, high arch, and subluxed metatarsophalangeal joints,
leading to excess pressure, callus formation, and ulcers
Peripheral sensory neuropathy Lack of protective sensation, leading to unattended minor
injuries caused by excess pressure or mechanical or ther-
mal injury
Peripheral autonomic neuropathy Deficient sweating leading to dry, cracking skin
Neuro-osteoarthropathic deformities (i.e., Charcot disease)
or limited joint mobility
Abnormal anatomy and biomechanics, leading to excess
pressure, especially in the midplantar area
Vascular (arterial) insufficiency Impaired tissue viability, wound healing, and delivery of
neutrophils
Hyperglycemia and other metabolic derangements Impaired immunological (especially neutrophil) function and
wound healing and excess collagen cross-linking
Patient disabilities Reduced vision, limited mobility, and previous amputation(s)
Maladaptive patient behaviors Inadequate adherence to precautionary measures and foot
inspection and hygiene procedures, poor compliance with
medical care, inappropriate activities, excessive weight-
bearing, and poor footwear
Health care system failures Inadequate patient education and monitoring of glycemic
control and foot care
thropathy. Clinical examination and imaging tests may suffice,
but bone biopsy is valuable for establishing the diagnosis of
osteomyelitis, for defining the pathogenic organism(s), and for
determining the antibiotic susceptibilities of such organisms
(B-II).
19. Although this field has matured, further research is
much needed. The committee especially recommends that ad-
equately powered prospective studies be undertaken to eluci-
date and validate systems for classifying infection, diagnosing
osteomyelitis, defining optimal antibiotic regimens in various
situations, and clarifying the role of surgery in treating oste-
omyelitis (A-III).
INTRODUCTION
Purpose of the guideline. Foot infections in persons with di-
abetes are a common, complex, and costly problem [1–4]. In
addition to causing severe morbidities, they now account for
the largest number of diabetes-related hospital bed–days [5]
and are the most common proximate, nontraumatic cause of
amputations [6, 7]. Diabetic foot infections require careful at-
tention and coordinated management, preferably by a multi-
disciplinary foot-care team (A-II) [8–13]. The team managing
these infections should preferably include, or have ready access
to, an infectious diseases specialist or a medical microbiologist
(B-III) [1]. Optimal management of diabetic foot infections
can potentially reduce the incidence of infection-related mor-
bidities, the need for and duration of hospitalization, and the
incidence of major limb amputation [14, 15]. Unfortunately,
these infections are frequently inadequately managed [16]. This
may result from a lack of understanding of current diagnostic
and therapeutic approaches, insufficient resources devoted to
the problem, or a lack of effective multidisciplinary collabo-
ration. The primary purpose of this guideline is to help reduce
the medical morbidity, psychological distress, and financial
costs associated with diabetic foot infections.
The focus of this guideline is primarily on managing the
diabetic patient with suspected or evident foot infection, be-
cause other published guidelines cover the general management
of the diabetic foot and diabetic foot ulceration [17–19]. The
committee members realize that the realities of primary care
practice and the scarcity of resources in some clinical situations
will restrict the implementation of some of the recommended
procedures and treatments. We believe, however, that in almost
all settings, high-quality care is usually no more difficult to
achieve or expensive than poor care and its consequences [20,
21].
This guideline should provide a framework for treating all
diabetic patients who have a suspected foot infection. Some
health care centers will be able to implement it immediately,
whereas others will need increased resources, better staff train-
ing, and intensified coordination of available expertise. Use of
this guideline may reduce the burdens (medical, financial, and
ecological) associated with inappropriate practices, including
those related to antibiotic prescribing, wound care, hospitali-
zation decisions, diagnostic testing, surgical procedures, and
adjunctive treatments. We hope it will contribute to reducing
the rates of lower extremity amputation, in line with the in-
ternational St. Vincent declaration [22]. Cost savings may en-
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Table 3. Pathogens associated with various clinical foot-infection syndromes.
Foot-infection syndrome Pathogens
Cellulitis without an open skin wound b-Hemolytic streptococcusa and Staphylococcus aureus
Infected ulcer and antibiotic naiveb S. aureus and b-hemolytic streptococcusa
Infected ulcer that is chronic or was previously treated with
antibiotic therapyc
S. aureus, b-hemolytic streptococcus, and
Enterobacteriaceae
Ulcer that is macerated because of soakingc Pseudomonas aeruginosa (often in combination with other
organisms)
Long duration nonhealing wounds with prolonged, broad-
spectrum antibiotic therapyc,d
Aerobic gram-positive cocci (S. aureus , coagulase-negative
staphylococci, and enterococci), diphtheroids, Enterobac-
teriaceae, Pseudomonas species, nonfermentative gram-
negative rods, and, possibly, fungi
“Fetid foot”: extensive necrosis or gangrene, malodorousc Mixed aerobic gram-positive cocci, including enterococci,
Enterobacteriaceae, nonfermentative gram-negative rods,
and obligate anaerobes
a Groups A, B, C, and G.
b Often monomicrobial.
c Usually polymicrobial.
d Antibiotic-resistant species (e.g., methicillin-resistant S. aureus, vancomycin-resistant enterococci, or extended-spectrum b-lactamase
producing gram-negative rods) are common.
sue, although this may be offset by an increased demand for
preventive foot care, diagnostic testing (especially MRI), and
vascular interventions [12].
Methodology. This guideline committee is comprised of
Infectious Diseases Society of America members with experi-
ence and interest in diabetic foot infections, many of whom
also have experience in writing guidelines. Committee members
are from several US states and other countries; their back-
grounds represent academia, bench and clinical research, in-
fectious diseases clinical practice, podiatry, and industry. Three
of the members are also members of the International Working
Group on the Diabetic Foot, which published its International
Consensus Guidelines on Diagnosing and Treating Diabetic
Foot Infections in 2003 [23]. After an extensive literature search
(which included the MEDLINE database, the EBSCO database,
the Cochrane Library, diabetic foot Web sites and bibliogra-
phies, and hand-searching of bibliographies of published ar-
ticles), committee members reviewed and discussed all available
evidence in a series of meetings and established consensus
through discussion and debate over a period of 3 years. Three
subcommittees drafted subsections that were modified and ex-
changed; these served as a basis for the final document, which
underwent numerous revisions that were based on both internal
and external reviews. Because of the relative paucity of ran-
domized controlled trials or other high-quality evidence in this
field, most of our recommendations are based on discussion
and consensus (B-II) (table 1) [24]. Thus, we elected to offer
a relatively brief summary and to provide an extensive bibli-
ography for those who would like to review the data themselves.
PATHOPHYSIOLOGY OF INFECTION
A diabetic foot infection is most simply defined as any infra-
malleolar infection in a person with diabetes mellitus. These
include paronychia, cellulitis, myositis, abscesses, necrotizing
fasciitis, septic arthritis, tendonitis, and osteomyelitis. The most
common and classical lesion, however, is the infected diabetic
“mal perforans” foot ulcer. This wound results from a complex
amalgam of risk factors [25, 26], which are summarized in
table 2. Neuropathy plays the central role, with disturbances
of sensory, motor, and autonomic functions leading to ulcer-
ation due to trauma or excessive pressure on a deformed foot
that lacks protective sensation. Once the protective layer of skin
is breached, underlying tissues are exposed to bacterial colo-
nization. This wound may progress to become actively infected,
and, by contiguous extension, the infection can involve deeper
tissues. This sequence of events can be rapid (occurring over
days or even hours), especially in an ischemic limb. Various
poorly characterized immunologic disturbances, especially
those that involve polymorphonuclear leukocytes, may affect
some diabetic patients, and these likely increase the risk and
severity of foot infections [27–30].
MICROBIOLOGY
Aerobic gram-positive cocci are the predominant microorgan-
isms that colonize and acutely infect breaks in the skin. S. aureus
and the b-hemolytic streptococci (groups A, C, and G, but
especially group B) are the most commonly isolated pathogens
[31–38]. Chronic wounds develop a more complex colonizing
flora, including enterococci, various Enterobacteriaceae, obli-
gate anaerobes, Pseudomonas aeruginosa, and, sometimes, other
nonfermentative gram-negative rods [39–43]. Hospitalization,
surgical procedures, and, especially, prolonged or broad-spec-
trum antibiotic therapy may predispose patients to colonization
and/or infection with antibiotic-resistant organisms (e.g.,
MRSA or vancomycin-resistant enterococci [VRE]) [44]. Al-
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Figure 1. Algorithm 1, part 1: approach to treating a diabetic patient with a foot wound
though MRSA strains have previously been isolated mainly
from hospitalized patients, community-associated cases are
now becoming common [45] and are associated with worse
outcomes in patients with diabetic foot infections [46–48]. Van-
comycin (or glycopeptide)–intermediate S. aureus has been iso-
lated in several countries. Of note, the first 2 reported cases of
vancomycin-resistant S. aureus each involved a diabetic patient
with a foot infection [49].
The impaired host defenses around necrotic soft tissue or
bone may allow low-virulence colonizers, such as coagulase-
negative staphylococci and Corynebacterium species (“diph-
theroids”), to assume a pathogenic role [43, 50]. Acute infec-
tions in patients who have not recently received antimicrobials
are often monomicrobial (almost always with an aerobic gram-
positive coccus), whereas chronic infections are often polym-
icrobial [31, 36, 43, 51]. Cultures of specimens obtained from
patients with such mixed infections generally yield 3–5 isolates,
including gram-positive and gram-negative aerobes and an-
aerobes [14, 34, 37, 38, 40, 41, 52–58]. The pathogenic role of
each isolate in a polymicrobial infection is often unclear. Table
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Table 5. Collection of soft-tissue specimens from an infected diabetic foot for culture.
When
7 Culturing clinically uninfected lesions is unnecessary, unless done as part of an infection-control surveillance protocol (C-III).
7 Cultures of infected wounds are valuable for directing antibiotic choices, but may be unnecessary in cases of acute mild
infection in an antibiotic-naive patient (B-III).
7 Blood cultures should be performed for a patient with a severe infection, especially if the patient is systemically ill (C-III).
How
7 Cleanse and debride the lesion before obtaining specimens for culture.
7 In cases involving an open wound, obtain tissue specimens from the debrided base (whenever possible) by means of curet-
tage (scraping with a sterile dermal curette or scalpel blade) or biopsy (bedside or operative) (A-I).
7 Avoid swabbing undebrided ulcers or wound drainage. If swabbing the debrided wound base is the only available culture
option, use a swab designed for culturing aerobic and anaerobic organisms and rapidly transport it to the laboratory (B-I).
7 Needle aspiration may be useful for obtaining purulent collections or, perhaps, a specimen from an area of cellulitis.
7 Clearly identify samples (specimen type and anatomic location), and promptly send them to the laboratory in an appropriate
sterile container or transport media for aerobic and anaerobic culture.
3 lists common clinical infection syndromes and the pathogens
most likely isolated in conjunction with them.
EVALUATING THE PATIENT, THE WOUND,
AND THE INFECTION
Diabetic patients may develop many types of foot wounds, any
of which can become infected. Infection should be diagnosed
clinically on the basis of the presence of purulent secretions
(pus) or at least 2 of the cardinal manifestations of inflam-
mation (redness, warmth, swelling or induration, and pain or
tenderness); not all ulcers are infected (figure 1) (B-II) [23].
Curing an infection often contributes to, but is not defined by,
healing of an ulcer. Management of diabetic foot infections
involves evaluating and determining the severity of infection
as the basis for selecting the appropriate approach to treatment
[15, 23, 40] (B-II). The issue of osteomyelitis is particularly
complex and problematic and is thus dealt with separately.
Evaluation of the infection should occur at 3 levels, as out-
lined in tables 4 and 5 (B-III): the patient as a whole, the
affected limb or foot, and the infected wound. The goal is to
determine the clinical extent (table 4) and the microbial etiology
(table 5) of the infection, the biology or pathogenesis of the
wound, any contribution of altered foot biomechanics to the
cause of the wound (and, thus, its ability to heal), any contri-
bution of vascular (especially arterial) disease, and the presence
of any systemic consequences of infection. Clinicians lacking
the skills or experience to conduct any of these assessments
should seek appropriate consultation.
DETERMINING THE SEVERITY OF INFECTION
The results of the evaluations described in table 4 can be used
to determine the overall severity of the infection and to for-
mulate a management plan (figure 2) (B-II). Unfortunately, the
lack of consensus on wound definitions and infection classi-
fication systems hampers comparison of published studies. The
Wagner system [15, 40, 98, 99] has been widely used for 25
years but was developed for the “dysvascular” foot, is skewed
toward severe disease, and contains all infections within a single
grade [100–105]. Consensus is developing that the key issues
in classifying a diabetic foot wound are its depth (in particular,
which tissues are involved) and whether the wound is com-
plicated by either ischemia or infection [23, 101, 106–108] (B-
II). The International Consensus on the Diabetic Foot recently
published a preliminary progress report on a diabetic foot ulcer
classification system for research purposes [23]. The key ele-
ments are summarized by the acronym PEDIS (perfusion, ex-
tent/size, depth/tissue loss, infection, and sensation). The
infection category includes grades 1 (no infection), 2 (involve-
ment of skin and subcutaneous tissue only), 3 (extensive cel-
lulitis or deeper infection), and 4 (presence of a systemic in-
flammatory response syndrome). Because this research-based
system is designed to be applicable to all ulcers, it includes a
category of grade 1 for uninfected lesions; grades 2–4 are similar
to those we describe in table 6.
For infected wounds (figure 2), the most important initial
task is to recognize patients who require immediate hospital-
ization, parenteral and broad-spectrum empirical antibiotic
therapy, and urgent consideration of diagnostic testing and
surgical consultation. We have defined these potentially life-
threatening infections as “severe.” Infections defined as “mild”
must be distinguished from clinically uninfected lesions but are
otherwise relatively easy to recognize. Defining infections as
“moderate” poses the greatest difficulty, because this term
covers a broad spectrum of wounds, some of which can be
quite complicated and even limb threatening. Other classifi-
cation schemes have used the terms “uncomplicated” and
“complicated” synonymously with mild and moderate, but we
wish to avoid confusion with the various complications that
can beset a wound. The distinction between moderate and
severe infections has less to do with the status of the foot than
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Figure 2. Algorithm 1, part 2: approach to treating a diabetic patient with a foot infection. 1Consider hospitalization if any of the following criteria
are present: systemic toxicity (e.g., fever and leukocytosis); metabolic instability (e.g., severe hypoglycemia or acidosis); rapidly progressive or deep-
tissue infection, substantial necrosis or gangrene, or presence of critical ischemia; requirement of urgent diagnostic or therapeutic interventions; and
inability to care for self or inadequate home support.
with the patient to whom it is attached. This distinction is
complicated by the fact that 50% of patients with a limb-
threatening infection do not manifest systemic signs or symp-
toms. After debating several classification schemes, we propose
the one presented in table 6 as a basis for subsequent discussions
in and beyond this guideline (B-II).
TREATMENT OF INFECTION
Avoid prescribing antibiotics for uninfected ulcerations.
Some argue that many apparently uninfected diabetic foot ul-
cers are actually subclinically infected—that is, they contain a
high “bioburden” of bacteria (usually defined as 1105 organisms
per gram of tissue) that results in “critical colonization” levels
and impairs wound healing [54, 109–114]. Available published
evidence does not support the use of antibiotics for the man-
agement of clinically uninfected ulcerations, either to enhance
wound healing or as prophylaxis against infection [115, 116].
Because antibiotic use encourages antimicrobial resistance, in-
curs financial cost, and may cause drug-related adverse effects,
we discourage therapy of uninfected ulcers. In some circum-
stances, it is difficult to decide whether a chronic wound is
infected, such as when the foot is ischemic, has abnormal col-
894 • CID 2004:39 (1 October) • Lipsky et al.
Table 6. Clinical classification of a diabetic foot infection.
Clinical manifestations of infection
Infection
severity
PEDIS
gradea
Wound lacking purulence or any manifestations of inflammation Uninfected 1
Presence of 2 manifestations of inflammation (purulence, or erythema, pain,
tenderness, warmth, or induration), but any cellulitis/erythema extends 2
cm around the ulcer, and infection is limited to the skin or superficial subcu-
taneous tissues; no other local complications or systemic illness.
Mild 2
Infection (as above) in a patient who is systemically well and metabolically sta-
ble but which has 1 of the following characteristics: cellulitis extending 12
cm, lymphangitic streaking, spread beneath the superficial fascia, deep-tissue
abscess, gangrene, and involvement of muscle, tendon, joint or bone
Moderate 3
Infection in a patient with systemic toxicity or metabolic instability (e.g., fever,
chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis,
severe hyperglycemia, or azotemia)
Severe 4
NOTE. Definitions of terms can be found in footnotes to table 4. Foot ischemia may increase the severity of any
infection, and the presence of critical ischemia often makes the infection severe. PEDIS, perfusion, extent/size, depth/
tissue loss, infection, and sensation.
a International Consensus on the Diabetic Foot [23].
oration or a fetid odor, has friable granulation tissue, is asso-
ciated with unexpected pain or tenderness, or when an oth-
erwise properly treated ulcer fails to show healing progress [117,
118]. In these unusual cases, a brief, culture-directed course of
antibiotic therapy may be appropriate (C-III).
Determine the need for hospitalization. Hospitalization is
the most expensive part of treating a diabetic foot infection,
and deciding on its necessity requires consideration of both
medical and social issues. Patients with infections that are either
severe or complicated by critical limb ischemia should generally
be hospitalized (C-III) [119, 120]. Some patients with appar-
ently mild infections and more patients with moderate infec-
tions may also need hospitalization; this may be for observation,
urgent diagnostic testing, or because complicating factors are
likely to affect their wound care or adherence to antibiotic
treatment. In the absence of these complicating features, most
patients with mild or moderate infections can be treated as
outpatients (A-II) [84, 121].
Stabilize the patient. Attending to the general metabolic
state of the patient is essential [25, 122]. This may involve
restoration of the fluid and electrolyte balances; correction of
hyperglycemia, hyperosmolality, acidosis, and azotemia; and
treatment of other exacerbating disorders. Critically ill patients
who require surgery should usually be stabilized before transfer
to the operating room, although surgery should usually not be
delayed for 148 h after presentation to the hospital (B-III)
[123]. The improvement of glycemic control may aid in both
eradicating the infection and healing the wound [124]. As the
infection improves, hyperglycemia may be easier to control.
Choose an antibiotic regimen. Selection of the antibiotic
regimen initially involves decisions about the route of therapy,
the spectrum of microorganisms to be covered, and the specific
drugs to administer and later involves choosing the definitive
regimen and the duration of treatment. Initial therapy is usually
empirical and should be based on the severity of the infection
and on any available microbiological data, such as recent culture
results or current Gram-stained smear findings. For severe in-
fections and for more-extensive, chronic moderate infections,
it is safest to commence therapy with broad-spectrum agents.
These should have activity against gram-positive cocci (includ-
ing MRSA in locations where this pathogen is common), as
well as gram-negative and obligate anaerobic organisms (B-III).
To ensure adequate and prompt tissue concentrations, therapy
should be given parenterally, at least initially (C-III). Although
some suggest broad-spectrum empirical therapy for most in-
fections [125–127], the majority of mild—and many moder-
ate—infections can be treated with agents with a relatively
narrow spectrum, such as those covering only aerobic gram-
positive cocci (A-II) [84]. Although anaerobic organisms are
isolated from many severe infections [42, 128], they are infre-
quent in mild-to-moderate infections [14, 84, 129], and there
is little evidence to support the need for antianaerobic therapy
in most infections (B-III). For mild-to-moderate infections in
patients without gastrointestinal absorption problems and for
whom an oral agent with the appropriate spectrum is available,
oral therapy is often appropriate, especially with highly bio-
available agents (A-II). For mildly infected open wounds with
minimal cellulitis, limited data support the use of topical an-
timicrobial therapy (B-I) [130].
Antibiotics vary in how well they achieve effective concen-
trations in infected diabetic foot lesions [131–137]; this is as-
sociated with the pharmacodynamic properties of the specific
agent and, especially, the arterial supply to the foot, rather than
with diabetes [138]. There are surprisingly few published clin-
ical trials of antibiotic therapy for diabetic foot infection. Sev-
eral antibiotic trials involving patients with various complicated
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skin and soft-tissue infections have included some patients with
diabetic foot infections. Table 7 provides a list of published
clinical trials that focused on therapy of diabetic foot infections,
either exclusively or as an identified subset of a larger study.
The lack of standardization among these trials makes the com-
parison of outcomes of different regimens inappropriate. The
differing definitions of infection severity and clinical end points
that were used in these publications highlight the need to de-
velop a consensus classification system for future studies. On
the basis of the available studies, no single drug or combination
of agents appears to be superior to others [129].
Table 8 summarizes some potential empirical antibiotic reg-
imens according to the clinical severity of the infection, al-
though the available data do not allow us to recommend any
specific antibiotic regimen for diabetic foot infections (B-II).
These suggested agents are derived from available published
clinical trials and our collective experience and are not meant
to be inclusive of all potentially reasonable regimens. Similar
agents could be used, depending on various clinical, micro-
biological, epidemiological, and financial considerations. Con-
sider modifying antibiotic therapy when culture and suscep-
tibility results are available (C-III). Empirical choices for
patients who are not responding to antibiotic therapy should
include agents that cover a different or more-extended spec-
trum of organisms (B-III) (figure 3). The regimens in table 8
are listed in approximate order of increasing broad-spectrum
coverage; the order does not indicate preferences by the com-
mittee. Dosages of antibiotic agents should be selected accord-
ing to suggestions of the US Food and Drug Administration,
the drug’s manufacturers, and the experience of the prescriber
and should be modified on the basis of any relevant organ
(especially renal) dysfunction and other clinical factors.
Determine the need for surgery. Many infections require
surgical procedures that range from drainage and excision of
infected and necrotic tissues to revascularization of the lower
extremity and reconstruction of soft-tissue defects or mechan-
ical misalignments [164–168]. Unfortunately, surgical treat-
ment of diabetic foot infections is based on even less-structured
evidence than that for antibiotic therapy [169]. Seek urgent
surgical consultation for life- or limb-threatening infections,
such as those presenting with necrotizing fasciitis, gas gangrene,
extensive soft-tissue loss, or evidence of compartment syn-
drome, or those in limbs with critical ischemia (A-II) [170,
171]. A surgical specialist should also evaluate patients who
have unexplained persistent foot pain or tenderness and/or
evidence of a deep-space infection, deep abscesses, or progres-
sive infection in the face of apparently appropriate medical care
(figure 3). Timely and aggressive surgical debridement, includ-
ing limited resections or amputations, may reduce the need for
more-extensive amputation (B-II) [172, 173]. Pus under pres-
sure, especially in an ischemic foot, can cause rapid and irrep-
arable damage. For patients with less-serious infections, it may
be appropriate to delay surgery to carefully observe the effec-
tiveness of medical therapy or to determine the demarcation
line between necrotic and viable tissue [174].
The surgeon must determine the adequacy of the blood sup-
ply to the remaining viable tissues, consider common operative
pitfalls (e.g., infection spreading among foot compartments, to
the deep plantar space, or along the tendon sheaths), and for-
mulate a strategy for eventual soft-tissue cover (e.g., primary
closure, delayed primary closure, secondary intention, or tissue
transfer) [175–177]. The surgical approach should optimize the
likelihood for healing and should attempt to preserve the in-
tegrity of the walking surface of the foot (B-II) [178]. In ad-
dition to manual dexterity, the surgeon must have sufficient
knowledge and experience to judge when and how to intervene.
The surgeon’s training specialty is less important than his or
her knowledge of the anatomy of the foot, the pathophysiology
of ulceration and infection, and experience with and enthusi-
asm for the field [8]. In most instances, the surgeon should
continue to observe the patient until the infection is under
control and the wound is healing (B-III).
In some cases, amputation is the best or only option [170,
179]. Urgent amputation is usually required only when there
is extensive necrosis or life-threatening infection [180]. Elective
amputation may be considered for the patient who has recur-
rent ulceration (despite maximal preventive measures), has ir-
reversible loss of foot function, or would require unacceptably
prolonged or intensive hospital care [181, 182]. Selection of
the level of amputation must take into consideration vascular,
reconstructive, and rehabilitation issues [183, 184]. Generally,
the surgeon should attempt to save as much of the limb as
possible. However, a higher-level amputation that results in a
more functional residual stump (even if a prosthesis is required)
may be a better choice than preserving a foot that is mechan-
ically unsound, unlikely to heal, or prone to future ulceration.
When all or part of a foot has dry gangrene, it may be preferable
(especially for a patient for whom surgery is a poor option) to
let the necrotic portions autoamputate. It may also be best to
leave adherent eschars in place, especially on the heel, until
they soften enough to be more easily removed, provided there
does not appear to be an underlying focus of infection [80,
81].
If the infected limb appears to be ischemic, the patient should
be referred to a surgeon with vascular expertise [185]. In most
cases, ischemia is due to larger-vessel atherosclerosis, rather
than to “small-vessel disease” [68]. Because vessels above the
knee and below the ankle tend to be relatively spared, lower-
extremity atherosclerosis may be amenable to angioplasty or
vascular bypass [186]. Patients with noncritical ischemia (e.g.,
those with an ankle to brachial artery blood pressure index of
0.5–0.9) can usually be successfully treated without a vascular
Table 7. Antibiotic agents used in published clinical studies of diabetic foot infections.
Antibiotic (route)
No. of
treated
patients Study design Patient group
Type/severity of
infection(s) Reference
Cephalosporins
Cefoxitin (iv) 8 Prospective,
noncomparative
Hospitalized Presumptive anaerobic [139]
Cefoxitin (iv) 23 RDBCT Hospitalized Moderate-to-severe [140]
Cefoxitin (iv) 60 Prospective,
noncomparative
Hospitalized Failing to respond to
therapy
[141]
Cefoxitin (iv) 18 RDBCT Hospitalized Mild-to-severe [142]
Cefoxitin (iv) alone 12 RCT Hospitalized Mixed [143]
Cefoxitin (iv) and amdino-
cillin (iv)
13 RCT Hospitalized Mixed [143]
Ceftizoxime (iv) 20 Prospective, uncontrolled Hospitalized PVD, moderate-to-severe [144]
Ceftizoxime (iv) 23 RDBCT Hospitalized Moderate-to-severe [140]
Cephalexin (po) 29 RDBCT Outpatient Mild-to-moderate [84]
Ceftriaxone (iv) 90 Prospective, observational Hospitalized Severe limb-threatening [145]
Penicillins
Ampicillin/sulbactam (iv)
(then amoxicillin/clavu-
lanate [po])
53 RCT Hospitalized initially Moderate [146]
Ampicillin/sulbactam (iv) 48 RDBCT Hospitalized Limb-threatening [147]
Ampicillin/sulbactam (iv) 74 Prospective,
noncomparative
Hospitalized Moderate-to-severe [148]
Ampicillin/sulbactam (iv) 18 RDBCT Hospitalized Mild-to-severe [142]
Ampicillin/sulbactam (iv)
and/or amoxicillin/clavu-
lanate (po)
120 RCT Outpatient or hospitalized All types [121]
Amoxicillin/clavulanate (iv/po) 191 Observational,
noncomparative
Mostly hospitalized Moderate [149]
Ticarcillin/clavulanate (iv) 28 RCT subgroupa Inpatient or outpatient Complicated soft-tissue [150]
Ticarcillin/clavulanate (iv) 17 RCT subgroupa Hospitalized Complicated soft-tissue [151]
Piperacillin/tazobactam (iv) 29 Prospective,
noncomparative
Hospitalized Moderate-to-severe [152]
Piperacillin/tazobactam
(iv/im)
38 Prospective
noncomparative
Outpatient Parenteral, mostly
moderate
[153]
Piperacillin/tazobactam (iv) 34 RDBCT subgroupa Hospitalized Severe [154]
Fluoroquinolones
Ciprofloxacin (po) 46 Prospective, randomized
doses
Hospitalized PVD [155]
Ciprofloxacin (iv, then po) 43 Prospective,
noncomparative
Hospitalized Soft-tissue or bone [156]
Ciprofloxacin (po) and
clindamycin (po)
120 Uncontrolled, quasi-
prospective
Hospitalized initially, re-
ceived other iv agents,
and was then dis-
charged home
Moderate-to-severe [157]
Ofloxacin (iv, then po) 55 RCT Hospitalized initially Moderate [146]
Ofloxacin (po) 420 RDBCT Outpatients Mild-to-moderately
infected ulcers
[130]
Levofloxacin (iv or po) 26 RCT subgroupa Outpatients or inpatients Complicated soft-tissue [150]
Trovafloxacin (po) 214 Prospective,
noncomparative
… Soft-tissue [158]
Clinafloxacin (iv, then po) 42 RDBCT subgroupa Hospitalized Severe [154]
Ofloxacin, levofloxacin, or
ciprofloxacin (iv and/or po)
90 Prospective, observational Hospitalized Severe limb-threatening [145]
Carbapenems
Imipenem/cilastatin (iv) 48 RDBCT Hospitalized Limb-threatening [147]
Imipenem/cilastatin (iv) 94 Uncontrolled,
noncomparative
Hospitalized Moderate-to-severe [159]
Imipenem/cilastatin (iv) 22 Randomized, open,
comparative
Hospitalized Wagner grade 2–4
wounds
[160]
Ertapenem (iv) 33 RDBCT Hospitalized Complicated soft-tissue [161]
(continued)
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Table 7. (Continued.)
Antibiotic (route)
No. of
treated
patients Study design Patient group
Type/severity of
infection(s) Reference
Miscellaneous agents
Aztreonam (iv) 20 Prospective subgroupa Hospitalized Acute, severe soft-tissue [162]
Clindamycin (po) 29 RDBCT Outpatient Mild-to-moderate [84]
Piperacillin/clindamycin (iv) 24 Randomized, open,
comparative
Hospitalized Wagner grade 2–4
wounds
[160]
Pexiganan (topical) 415 RDBCT Outpatient Mild-to-moderate infected
ulcers
[130]
Linezolid (iv or po) 241 RCT Outpatient or hospitalized All types [121]
Daptomycin (iv) 50 RCT subgroupa Hospitalized Complicated skin [163]
NOTE. Trials are those in which the purpose of the study was to examine the efficacy of antibiotic therapy, and the subjects were exclusively,
predominantly, or separately identifiable as diabetic patients with foot infections. The clinical and microbiological outcomes were not consistently
defined or routinely provided. PVD, peripheral vascular disease; RCT, randomized controlled trial; RDBCT, randomized, double-blinded, controlled trial
(each arm is listed separately in the table).
a Involved patients with diabetic foot infections who constituted an identified subgroup of a larger trial of skin and skin structure infections.
procedure. For more-severe vascular disease of the foot, many
centers have reported successful use of femoral-distal bypass
procedures in diabetic patients [186–189]. For a patient with
a severely infected ischemic foot, it is usually preferable to
perform any needed revascularization early after recognizing
the infection (i.e., within 1–2 days), rather than to delay this
procedure in favor of prolonged (and potentially ineffective)
antibiotic therapy (B-II) [123, 190]. On the other hand, careful
debridement of necrotic infected material should not be delayed
while awaiting revascularization. Optimal surgical management
may require multiple, staged procedures [191].
Formulate a wound-care plan. The wound may require
additional attention after the debridement performed during
the initial assessment (table 4). The goal is to physically excise
dead and unhealthy tissue, thereby enabling wound healing and
removing a reservoir of potential pathogens [82, 192–194]. Any
experienced clinician may perform limited debridement. This
can usually be undertaken as a clinic or bedside procedure and
without anesthesia, especially for a neuropathic foot. Sharp
debridement with scalpel, scissors, or tissue nippers is generally
preferable to hydrotherapy or topical debriding agents, which
are less definitive and controllable and may require prolonged
and repeated applications (B-III) [194, 195]. There are many
wound-care products that are touted as being able to improve
healing in various ways [17, 23, 196–199], but a discussion of
these is beyond our scope. The infected wound should be
dressed in a manner that allows daily inspection and encourages
a moist wound-healing environment (B-III). No evidence fa-
vors any particular type of dressing; convenience and cost are
important considerations. Removal of pressure from a foot
wound (i.e., off-loading) is crucial to the healing process (A-
I) [200, 201]. Many types of devices can off-load the infected
wound, but it is important to choose one that permits easy
inspection [202].
Adjunctive treatments. Investigators and industry repre-
sentatives have advocated many types of wound-care treat-
ments, including wound vacuum-drainage systems [203–206],
recombinant growth factors [207–212], skin substitutes [203,
213–216], antimicrobial dressings [217–219], and maggot (ster-
ile larvae) therapy [220–222]. Although each treatment likely
has some appropriate indications, for infected wounds, avail-
able evidence is insufficient to recommend routine use of any
of these modalities for treatment or prophylaxis.
Two adjunctive modalities do deserve brief comments. First,
granulocyte colony-stimulating factors (G-CSFs) have now
been investigated in 5 randomized trials involving diabetic foot
infections [223–227]. A preliminary meta-analysis of these trials
suggests that G-CSF does not accelerate resolution of infection
but may significantly reduce the need for operative procedures
(B-I) [228]. Second, several anecdotal and retrospective reports
suggest that hyperbaric oxygen therapy may be of value for
treatment of diabetic foot wounds, and a few recent prospective
studies have shown promising results [229–232]. A recent
Cochrane review concluded that hyperbaric oxygen therapy
significantly reduced the risk of major amputation related to a
diabetic foot ulcer [233] (B-I). Only additional randomized
clinical trials can establish when, for whom, and with what
protocols these expensive and limited resources might be used
in the treatment of diabetic foot infections. Neither should be
used as a substitute for proper surgical debridement and con-
ventional therapy.
FOLLOW-UP
Careful observation of the patient’s response to therapy (figure
4) is essential and should be performed daily for inpatients and
perhaps every 2–5 days initially for outpatients (B-III). The
primary indicators of improvement are resolution of local and
systemic symptoms and clinical signs of inflammation. Blood
test findings, including WBC counts [234, 235] and inflam-
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Table 8. Suggested empirical antibiotic regimens, based on clinical severity, for diabetic foot infections.
Route and agent(s) Mild Moderate Severe
Advised route Oral for most Oral or parenteral, based
on clinical situation and
agent(s) selected
Intravenous, at least
initially
Dicloxacillin Yes … …
Clindamycin Yes … …
Cephalexin Yes … …
Trimethoprim-sulfamethoxazole Yes Yes …
Amoxicillin/clavulanate Yes Yes …
Levofloxacin Yes Yes …
Cefoxitin … Yes …
Ceftriaxone … Yes …
Ampicillin/sulbactam … Yes …
Linezolida (with or without aztreonam) … Yes …
Daptomycina (with or without aztreonam) … Yes …
Ertapenem … Yes …
Cefuroxime with or without metronidazole … Yes …
Ticarcillin/clavulanate … Yes …
Piperacillin/tazobactam … Yes Yes
Levofloxacin or ciprofloxacin with clindamycin … Yes Yes
Imipenem-cilastatin … … Yes
Vancomycina and ceftazidime (with or without
metronidazole)
… … Yes
NOTE. Definitive regimens should consider results of culture and susceptibility tests, as well as the clinical response to the empirical
regimen. Similar agents of the same drug class may be substituted. Some of these regimens may not have US Food and Drug Administration
approval for complicated skin and skin-structure infections, and only linezolid is currently specifically approved for diabetic foot infections.
a For patients in whom methicillin-resistant S. aureus infection is proven or likely.
matory markers, such as the erythrocyte sedimentation rate
[122, 236, 237] and the C-reactive protein level [238], are of
limited use for monitoring response, although is it reassuring
to see elevated levels decrease and cause for concern when they
do not.
When a hospitalized patient is ready for discharge or an
outpatient returns for follow-up, the clinician should accom-
plish 4 tasks (figures 1, 2, and 4).
1. Select the definitive antibiotic regimen. Review the culture
and drug susceptibility results and inquire about any adverse
effects related to the current antibiotic therapy. Choose a de-
finitive antibiotic regimen (including the treatment duration)
on the basis of the results of cultures, imaging, or other in-
vestigations, and the initial clinical response (C-III). It is not
always necessary to cover all microorganisms isolated from cul-
tures. More virulent species (e.g., S. aureus and group A or B
streptococci) should always be covered, but in a polymicrobial
infection, less-virulent bacteria (e.g., coagulase-negative staph-
ylococci and enterococci) may be less important (B-II). If the
infection has not responded to the empirical regimen, select
agents with activity against all isolates. For a clinically stable
patient who has had 1 unsuccessful courses of therapy, con-
sider discontinuing antimicrobials for a few days and then col-
lecting optimal specimens for culture (C-III).
2. Re-evaluate the wound. Inspect the site to ensure that
the infection is responding and that the wound is healing. If
neither is occurring, reassess the need for surgical intervention.
No evidence supports giving antibiotics for the entire time that
the wound remains open. Antibiotics should be used for a
period defined by the biology of the infection and by the clinical
syndrome, as suggested in table 9 (A-II). If clinical evidence of
infection persists beyond the expected duration, check on the
patient’s compliance with antibiotics and re-evaluate for un-
addressed adverse biological factors (figure 3). These may in-
clude the development of antibiotic resistance, a superinfection,
an undiagnosed deep abscess or case of osteomyelitis, or is-
chemia that is more severe than was initially suspected.
3. Review the off-loading and wound care regimens. Deter-
mine the effectiveness of, and the patient’s compliance with,
the prescribed regimens. Suggest (or seek consultation for) al-
ternatives when necessary.
4. Evaluate glycemic control. Ensure that blood glucose lev-
els and other aspects of the patient’s metabolic status are ad-
equately controlled.
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Figure 3. Algorithm 1, part 3: approach to assessing a diabetic patient with a foot infection who is not responding well to treatment. TcPO2,
transcutaneous partial pressure of O2.
OSTEOMYELITIS
Dealing with osteomyelitis is perhaps the most difficult and
controversial aspect in the management of diabetic foot infec-
tions [239–244]. First among several problems is that the lack
of a consensus definition of the disease hinders the comparison
of available studies and experiences. Next, there are many avail-
able diagnostic tests, but they often yield equivocal results. Fur-
thermore, the presence of osteomyelitis increases the likelihood
of surgical intervention, including amputation, and the re-
quired duration of antibiotic therapy [240]. Finally, osteomy-
elitis impairs healing of the overlying wound and acts as a focus
for recurrent infection.
When to consider the diagnosis. Consider osteomyelitis as
a potential complication of any deep or extensive ulcer, espe-
cially one that is chronic or overlies a bony prominence (figure
5) [245]. Suspect underlying osteomyelitis when an ulcer does
not heal after at least 6 weeks of appropriate care and off-
loading. Any ulcer in which bone is either visible or can be
easily palpated with a sterile blunt metal probe is likely to be
complicated by osteomyelitis [83]. In patients with a limb-
threatening infection, positive results of a probe-to-bone test
may be taken as nearly sufficient for diagnosis, but the per-
formance characteristics of this test have not yet been fully
defined. A swollen foot in a patient with a history of foot
900 • CID 2004:39 (1 October) • Lipsky et al.
Figure 4. Algorithm 2: approach to selecting antibiotic therapy for a diabetic patient with a foot infection. MRSA, methicillin-resistant Staphylococcus
aureus.
ulceration, a “sausage toe” (i.e., a red, swollen digit) [246], or
an unexplained high WBC count [235] or inflammatory mark-
ers [236] should also arouse suspicion of osteomyelitis (B-II).
Finally, radiologically evident bone destruction beneath an ulcer
should be considered to represent osteomyelitis unless proven
otherwise [247].
Confirming the diagnosis. Because bony destruction is
usually not seen on plain radiography performed during the
early stages of disease and neuro-osteoarthropathy can mimic
infection, diagnosing osteomyelitis at the time the patient first
presents to the hospital can be difficult [248–250]. Character-
istic progressive changes on serial plain radiographs may help
in more-chronic cases [247, 251]. Radioisotope scans are more
sensitive than radiographs for detecting osteomyelitis during
the early stages of this diseases, but they are expensive and can
be time-consuming [252]. The reported performance charac-
teristics of various types of nuclear medicine scans varies, but
the specificity of technetium bone scans is generally low [240,
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Table 9. Suggested route, setting, and durations of antibiotic therapy, by clinical syndrome.
Site, by severity or
extent, of infection Route of administration Setting for therapy Duration of therapy
Soft-tissue only
Mild Topical or oral Outpatient 1–2 Weeks; may extend
up to 4 weeks if slow
to resolve
Moderate Oral (or initial parenteral) Outpatient/inpatient 2–4 Weeks
Severe Initial parenteral, switch to oral
when possible
Inpatient, then
outpatient
2–4 Weeks
Bone or joint
No residual infected tissue
(e.g., post-amputation)
Parenteral or oral … 2–5 Days
Residual infected soft tissue
(but not bone)
Parenteral or oral … 2–4 Weeks
Residual infected (but viable)
bone
Initial parenteral, then consider
oral switch
… 4–6 Weeks
No surgery, or residual dead
bone postoperatively
Initial parenteral, then consider
oral switch
… 13 Months
253–255]. MRI is the most useful of the currently available
imaging modalities (A-I) [90, 92, 94, 256–259]. MRI is the
most accurate imaging study for defining bone infection, and
it also provides the most reliable image of deep soft-tissue
infections. The performance characteristics of all these diag-
nostic tests are highly correlated with the pretest probability of
osteomyelitis, and they are most useful for intermediately prob-
able cases [260]. The criterion (gold) standard for diagnosing
osteomyelitis is isolation of bacteria from a reliably obtained
sample of bone (using measures to minimize contamination)
concomitant with histological findings of inflammatory cells
and osteonecrosis (B-II). Unfortunately, few of the studies that
have evaluated diagnostic tests or have assessed treatment out-
comes have used this standard.
MRI is usually not needed as a first-line investigation in cases
of diabetic foot infection. When osteomyelitis is a possibility,
obtaining plain radiographs often suffices. If these radiographs
show no evidence of pathological findings in bone, the patient
should be treated for ∼2 weeks for the soft-tissue infection. If
suspicion of osteomyelitis persists, perform plain radiography
again 2–4 weeks later. If the initial films show classic changes
suggestive of osteomyelitis (cortical erosion, periosteal reaction,
and mixed lucency and sclerosis), and if there is little likelihood
of a noninfectious osteoarthropathy, treat for presumptive os-
teomyelitis, preferably after obtaining appropriate specimens
for culture (B-III). If findings of radiography are only consistent
with, but not characteristic of, osteomyelitis, one of the fol-
lowing choices should be considered.
1. Additional imaging studies. MRI is the preferred imaging
study, with nuclear medicine scans (that preferably use newer
generation leukocyte [239, 261, 262] or immunoglobulin [263,
264] techniques) being a second choice. If results of the imaging
tests are negative, osteomyelitis is unlikely; if results suggest
osteomyelitis, consider whether bone biopsy is needed (vide
infra).
2. Empirical treatment. Provide antibiotic therapy for an-
other 2–4 weeks and then perform radiograph again to deter-
mine whether bony changes have progressed (which would
suggest infection).
3. Bone biopsy. Use an appropriate procedure, as defined
below. Collection of a sample of a bony lesion (either opera-
tively or percutaneously) is recommended if the diagnosis re-
mains in doubt after imaging or if osteomyelitis is likely but
the etiologic agent or antibiotic susceptibilities are not pre-
dictable (B-II) [251, 265–268]. Some physicians would also
obtain biopsy specimens of most mid- or hind-foot lesions,
because these are more difficult to treat and more often lead
to a high-level (i.e., above the ankle) amputation. Any properly
trained physician (e.g., an orthopedic surgeon, podiatrist, in-
terventional radiologist) can perform the biopsy. Percutaneous
biopsy should preferably be done under fluoroscopic or CT
guidance, traversing uninvolved skin if possible. For patients
with sensory neuropathy, anesthesia may be unnecessary. Var-
ious types of bone-cutting needles, such as Jamshidi (Perfectum
Corporation; distributed by Propper and Sons) and Ostycut
(Bard Products; distributed by Angiomed) have been used. Ob-
tain 2–3 specimens if possible, sending at least 1 for culture
and another for histological analysis [269]. With small toe
bones, it may only be possible to aspirate a few bony spicules.
We found no published reports of complications of foot bone
biopsy and consider it to be a safe procedure (B-II). Cultures
of bone specimens provide more accurate microbiologic data
than do those of soft-tissue specimens for patients with oste-
omyelitis [93, 268, 270].
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Figure 5. Algorithm 3: evaluating a diabetic patient who has suspected osteomyelitis of the foot. 1Cortical erosion, periosteal reaction, lucency
and sclerosis, sequestrum, or involcrum. 2May be done percutaneously or operatively, preferably after antibiotic therapy has been stopped for 1–2
weeks (if safe to do so).
Choosing between medical and surgical therapy. Trad-
itionally, authorities have believed that resecting a bone with
chronic osteomyelitis was essential for cure [240, 265]. Recently,
some have disputed the routine need for surgical resection
[239]. Definitive surgical solutions to osteomyelitis, such as ray
and transmetatarsal amputations, may risk architectural reor-
ganization of the foot, resulting in altered biomechanics and
additional cycles of ulceration. Neuropathy and reduced sys-
temic manifestations of infection may make osteomyelitis tol-
erable for the patient, who may thus opt for attempts at medical
management. By contrast, these diabetic complications may
also mask progressive bone destruction, with delayed or in-
adequate surgery resulting in poorly controlled infection, ad-
ditional bone or soft-tissue necrosis, and a nonhealing wound.
These arguments have led some health care professionals to
treat diabetic foot osteomyelitis with little or no surgical in-
tervention [239]. Published reports on nonsurgical treatment
with a prolonged (3–6 months) course of antibiotics have re-
ported clinical success in ∼65%–80% of cases [155, 173, 237,
243, 271–276]. Unfortunately, these nonrandomized case series
often fail to specify a definition of osteomyelitis, how patients
were selected, whether patients were enrolled prospectively or
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even consecutively, and how much nonoperative debridement
of bone was performed. The determination of which patients
are suitable for nonsurgical treatment, as well as what duration
of antibiotic therapy is needed, are important areas for future
study. Meanwhile, there are 4 cases in which nonsurgical man-
agement of osteomyelitis might be considered (B-II).
1. There is no acceptable surgical target (i.e., radical cure
of the infection would cause unacceptable loss of function).
2. The patient has ischemia caused by unreconstructable
vascular disease but desires to avoid amputation.
3. Infection is confined to the forefoot, and there is min-
imal soft-tissue loss.
4. The patient and health care professional agree that sur-
gical management carries excessive risk or is otherwise not
appropriate or desirable.
When therapy for osteomyelitis fails, consider several issues.
First, was the original diagnosis correct? Second, is there re-
sidual necrotic or infected bone or surgical hardware that
should be resected or removed? Third, did the selected anti-
biotic regimen likely cover the causative organism(s) and
achieve adequate levels in bone, and was it administered for a
sufficient duration? Fourth, was the failure to eradicate bone
infection the real cause of the current wound problem? Each
case needs an individualized approach, usually in consultation
with a knowledgeable surgeon. Selected patients may benefit
from implanted antibiotics (e.g., embedded in beads or cement)
[277–280], hyperbaric oxygen therapy, or revascularization,
whereas others may elect long-term or intermittent antibiotic
suppression or, in some cases, amputation.
Selecting an antibiotic regimen. The most appropriate du-
ration of therapy for any type of diabetic foot infection has not
been well defined [129]. It is important to consider the presence
and amount of any residual dead or infected bone and the state
of the soft tissues. When a radical resection leaves no remaining
infected tissue, minimal antibiotic therapy is needed (B-II).
Alternatively, if infected bone or soft tissue remain despite sur-
gery, continued prolonged treatment is necessary. For osteo-
myelitis, some parenteral therapy may be beneficial, especially
if an agent with suboptimal bioavailability is used (C-III). Par-
enteral therapy may be delivered in the outpatient setting, where
available [153, 281, 282]. Our recommendations for duration
of therapy are based on the clinical syndrome and are sum-
marized in table 9.
OUTCOMES
The goals of treating a diabetic foot infection are the eradication
of clinical evidence of infection and the avoidance of soft-tissue
loss and amputations. Overall, expect a good clinical response
(i.e., resolution of clinical evidence of infection) to appropriate
therapy in 80%–90% of mild-to-moderate infections [84, 121,
130, 263] and in 60%–80% of severe infections or cases of
osteomyelitis [130, 145, 147, 237, 283]. Factors associated with
a poor outcome include signs of systemic infection [237], in-
adequate limb perfusion, osteomyelitis [273, 283–285], the
presence of necrosis or gangrene [276], an inexperienced sur-
geon [286], and proximal location of the infection [287]. Re-
lapses occur in ∼20%–30% of patients, especially in those with
osteomyelitis; relapses may be difficult to differentiate from a
reinfection. A recent survey of members of the Emerging In-
fections Network found that the acceptable median failure rate
for treating diabetic foot osteomyelitis was 18% [288]. Con-
ducting systematic audits of outcomes and patient treatment
processes may be useful for individual practitioners and for
multidisciplinary foot-care teams (B-II).
PREVENTION
A patient who has had 1 foot infection is more likely to have
another, making this a good time to reinforce preventive actions
with the patient [11, 289, 290]. Detection of neuropathy before
its complications ensue is the best method to prevent foot
infections. Educate the patient about the importance of opti-
mizing glycemic control, using appropriate footwear at all
times, avoiding foot trauma, performing daily self-examination
of the feet, and reporting any changes to health care profes-
sionals (A-II). Because basic screening can be completed in a
few minutes, clinicians should reinforce these preventive mea-
sures by questioning patients about foot care and regularly
examining their feet and shoes. Patients with severe neuropathy,
substantial foot deformity, or critical ischemia should be re-
ferred to appropriate specialists to deal with these problems
(A-II).
RECOMMENDED RESEARCH
Few of the recommendations in this guideline are based on
properly designed and adequately powered randomized studies.
There are 6 areas in which future research would be particularly
helpful (A-III).
1. Establish a robust, validated, simple classification system
for infected foot lesions to facilitate multicenter comparative
studies of their natural history, diagnosis, and treatment. We
support efforts to validate the International Consensus PEDIS
system for foot-ulcer research purposes.
2. Determine whether there is a role for antibiotic therapy
in managing clinically uninfected ulcers.
3. Determine optimal antibiotic regimens (agents, routes,
and duration) for various types of soft-tissue and bone
infections.
4. Establish a consensus definition of osteomyelitis in the
diabetic foot.
5. Design and validate a simple, cost-effective algorithm
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for the diagnosis and treatment of infections, especially
osteomyelitis.
6. Compare the outcomes of surgical and nonsurgical man-
agement of osteomyelitis.
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